NCT06077877View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

June 29, 2027

Study Completion Date

June 29, 2027

Conditions
Neoplasms
Interventions
DRUG

GSK4524101

GSK452101 will be administered.

DRUG

Niraparib

Niraparib will be administered.

Trial Locations (9)

22031

RECRUITING

GSK Investigational Site, Fairfax

63110

RECRUITING

GSK Investigational Site, St Louis

75230

RECRUITING

GSK Investigational Site, Dallas

77030

RECRUITING

GSK Investigational Site, Houston

78229

RECRUITING

GSK Investigational Site, San Antonio

94158

RECRUITING

GSK Investigational Site, San Francisco

T6G 1Z2

RECRUITING

GSK Investigational Site, Edmonton

M5G 2M9

RECRUITING

GSK Investigational Site, Toronto

H4A 3J1

RECRUITING

GSK Investigational Site, Montreal

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06077877 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter